The Treatment Landscape for Thyroid Carcinoma Will Change Dramatically Through
Uptake of Emerging Agents for Differentiated Thyroid Carcinoma Will Be
Constrained by Small Patient Populations in the Locally Advanced or Advanced
Radioiodine-Refractory Setting, According to Findings from Decision Resources
BURLINGTON, Mass., Feb. 4, 2013
BURLINGTON, Mass., Feb. 4, 2013 /PRNewswire/ -- Decision Resources, one of the
world's leading research and advisory firms for pharmaceutical and healthcare
issues, finds that, through 2021, the treatment landscape for thyroid
carcinoma will change dramatically in the United States and Europe due to the
expected approval of several new therapies. In addition to Exelixis's Cometriq
(cabozantinib) for advanced medullary thyroid carcinomas (MTC)—which was
approved in the U.S. late last year—the other emerging agents in the thyroid
carcinoma space are Bayer HealthCare/Onyx Pharmaceuticals' Nexavar
(sorafenib), Eisai's lenvatinib, Genentech/Roche's Zelboraf (vemurafenib),
GlaxoSmithKline's combination of dabrafenib and trametinib and OXiGENE's
Zybrestat (fosbretabulin). A large focus of drug development has been on the
radioiodine (RAI)-refractory, differentiated thyroid carcinoma (DTC) patient
"These therapies will likely be high priced but will dramatically increase
treatment options for RAI-refractory thyroid carcinoma patient populations for
which there is no standard of care," said Decision Resources Analyst Gemma
According to Niche Markets and Rare Diseases: Thyroid Carcinoma, the overall
incidence of thyroid carcinoma will increase over the next decade, driven by
demographic change and more sensitive diagnostic procedures. In particular,
the incidence of papillary thyroid carcinoma (PTC), which accounts for the
vast majority of all diagnosed cases of thyroid carcinoma, will rise. In 2021,
the number of incident cases of PTC will increase by approximately 23 percent,
thereby contributing to an increase in the size of the drug-treatable
The report also finds that the opportunity for uptake of emerging agents
developed for DTC will be constrained by small patient populations in the
locally advanced or advanced disease setting. The majority of DTC cases are
usually diagnosed early and have a good prognosis with current treatment of
surgery, typically a total thyroidectomy, and RAI ablation therapy.
"Surgery and RAI therapy is the primary treatment approach for patients whose
disease is considered resectable and the tumor is RAI-avid," Dr. McConnell
said. "As long as a patient remains RAI-avid, RAI will remain the treatment of
choice, constraining the opportunity for emerging therapies."
About Thyroid Carcinoma
Thyroid Carcinoma is offered as part of Decision Resources' Niche Markets and
Rare Diseases service. Each report assesses opportunity in a select drug
market across the United States, France, Germany, Italy, Spain and the United
Kingdom. The report provides detailed coverage of patient populations, current
therapies, unmet needs and emerging therapies, and includes primary research
with country-specific thought leaders.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market
research publications, advisory services and consulting designed to help
clients shape strategy, allocate resources and master their chosen markets.
Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group at
All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.
SOURCE Decision Resources
Contact: Decision Resources, Christopher Comfort, +1-781-993-2597,
Press spacebar to pause and continue. Press esc to stop.